Pharmafile Logo
Pharmafocus logo
Advanced Search

Prolia

Showing 9 posts of 9 posts found.

amgen_hq

Amgen’s Prolia achieves positive top-line Phase III results after 12 months

August 30, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …

News
amgen_flag

Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study

June 21, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics

US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …

News
Amgen image

Amgen files high earnings for Q1

April 22, 2015
Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis

Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …

News
Amgen HQ

Amgen to wield axe on 2,900 jobs

July 30, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, Prolia, job cuts

Amgen has announced this morning that it will make swingeing cuts in the US over the next two years as …

News

Amgen bone cancer drug Xgeva approved in Europe

July 18, 2011
Sales and Marketing Amgen, Prolia, Xgeva, denosumab

Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …

News

Denosumab approved for bone cancer use

November 19, 2010
Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab

Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …

News
Amgen's Prolia

NICE halts Prolia appraisal

August 2, 2010
Sales and Marketing Amgen, NICE, Prolia

NICE says it has been forced to terminate a review of Amgen’s bone density drug Prolia after the US biotech …

News

Prolia gets early thumbs up from NICE

June 18, 2010
Sales and Marketing Amgen, NICE, Prolia

Amgen’s new treatment to prevent bone fractures caused by osteoporosis has been given preliminary approval from the UK’s cost effectiveness …

News

Amgen’s Prolia approved in Europe

June 1, 2010
Sales and Marketing Amgen, Prolia

A blockbuster future is predicted for the osteoporosis treatment Prolia, with global sales predicted to reach $5 billion.European regulators have …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025